Proterris Overview

Founded 2012
Status Private
Latest Deal Type Series A
Latest Deal Amount $2M
Latest Deal Amount
Investors 4

Proterris General Information


Developer of clinical-development stage therapeutic applications intended to focus on inhaled and small-molecule carbon monoxide. The company's applications include demonstrated anti-fibrotic, anti-inflammatory and cytoprotective properties, enabling patients to avail CO for delayed graft function (DGF) in renal transplant recipients and idiopathic pulmonary fibrosis (IPF).

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Primary Office
  • 33 Broad Street
  • Boston, MA 02109
  • United States

Proterris Timeline

Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Proterris Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 16-Aug-2019 $2M 000 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 31-Dec-2017 Completed Startup
2. Grant $22.7M Completed Startup
1. Accelerator/Incubator Completed Startup

Proterris Cap Table

To view Proterris‘s complete cap table, request access >>
Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.00

Proterris Executive Team (5)

Name Title Board Seat Contact Info
Jeffrey Wager MD Co-Founder, Chief Executive Officer & Chairman
Joseph Wager Co-Founder, Vice President, Business Development and Board Observer
Augustine Choi MD Co-Founder
Kourosh Saeb-Parsy Ph.D Acting Chief Medical Officer
Benjamin Perrone Chief Financial Officer & Director, Finance and Business Development

Proterris Board Members (4)

Name Representing Role Since
Donald DeBethizy Ph.D Self Board Member 000 0000
Jeffrey Wager MD Proterris Co-Founder, Chief Executive Officer & Chairman 000 0000
Matthew Bennett JD Self Board Member 000 0000
Peter Hutt JD Self Board Member 000 0000

Proterris Investors (4)

To view Proterris‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Columbia Technology Ventures University Minority 000 0000 000000 0
Portugal Ventures Venture Capital Minority 000 0000 000000 0
Johns Hopkins Technology Ventures Accelerator/Incubator 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0

Proterris Acquisitions (1)

To view Proterris‘s complete investment and acquisition history, request access >>
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 31-Dec-2017 000000000000000000 Biotechnology 0000000 00000 00

Ready to get started?

Request a free trial